Innate Pharma (IPHA)
(Delayed Data from NSDQ)
$2.46 USD
+0.06 (2.50%)
Updated Apr 26, 2024 03:40 PM ET
After-Market: $2.48 +0.02 (0.81%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
IPHA 2.46 +0.06(2.50%)
Will IPHA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for IPHA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IPHA
All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy
Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study
IPHA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Innate (IPHA) Gains as Blood Cancer Drug Gets Fast Track Tag
Sanofi (SNY) Dupixent Gets CHMP Nod to Eosinophilic Esophagitis
Other News for IPHA
Buy Rating Affirmed for Innate Pharma Amidst Promising Platforms and Strategic Growth Potential
Innate Pharma doses first patient in Sanofi-sponsored trial of SAR443579
Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
Innate Pharma: A Strong Buy on IPH45’s Promising Data and Solid Financial Projections